Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Joanne Mansell is active.

Publication


Featured researches published by Joanne Mansell.


International Journal of Radiation Oncology Biology Physics | 1987

An update on malignant salivary gland tumors treated with neutrons at fermilab

K.R. Saroja; Joanne Mansell; Frank R. Hendrickson; Lionel Cohen; A. J. Lennox

One hundred and thirteen cases of recurrent and/or unresectable malignant salivary gland tumors, treated with fast neutron therapy at Fermilab between September 1976 and December 1984, are analyzed for local control, sites of failure, and treatment-related morbidity. Sixty-three patients had major and 55 had minor salivary gland tumors. Local control was achieved in 67% of patients with major and 58% of patients with minor salivary gland tumors. In the subgroup of patients with oropharyngeal and oral cavity lesions, 19/24 (80%) had local control. However, only four of 15 patients with maxillary antrum tumors had successful control of their disease. Seventy-four percent of patients with lesions measuring 5 cm or less and 30% of patients with larger lesions had their local disease controlled. Histology did not influence the local control rate. Both observed and adjusted median survival for patients with major salivary gland tumors was 36 months. Disease-free survival was 31 months. Observed and adjusted median survivals for patients with minor salivary gland tumors are 48 and 57 months respectively. Twenty of 86 patients (23%) had major morbidity; this was directly related to the total dose delivered. In the dose range 20-24 Gy the complication rate was 16%. Most of these complications were successfully managed with minimal functional disability. We have concluded that fast neutron irradiation is an appropriate treatment for malignant salivary gland tumors.


Cancer | 1985

Response of pancreatic cancer to local irradiation with high‐energy neutrons

Lionel Cohen; Katherine H. Woodruff; Frank R. Hendrickson; Parvathy D. Kurup; Joanne Mansell; Miguel Awschalom; I. Rosenberg; Randall K. Ten Haken

Seventy‐seven patients with locally advanced, nonresectable, biopsy‐proven adenocarcinoma of the pancreas were treated by palliative bypass surgery followed by intensive neutron beam irradiation of the primary tumor site. Three dose levels, under 20, 21 to 23, and 24 to 25 Gy, were studied with the use of a treatment plan that included all known disease within a limited target volume, generally under 21. Symptomatic palliation was achieved in the majority of patients. The median survival time was 6 months. One patient remained alive and well without evidence of tumor 5 years after irradiation. Two were free of tumor at autopsy (one had died of intercurrent disease and one of radiation‐related complications). A common cause of death was metastatic dissemination. Complication rates were dosedependent; life‐threatening complications did not exceed 12% with doses of less than 23 Gy. Autopsies from 19 patients were reviewed. In all, the pancreatic tumor site showed extensive reactive fibrosis. Local control was achieved in two patients, but most had both residual tumor in the pancreas and metastases. Six patients had centrolobular veno‐occlusive liver disease. These patients had all received the higher (22–24 Gy) neutron doses. Six patients had hemorrhagic radiation gastroenteritis. Mild skin atrophy and bone marrow hypoplasia were seen in the irradiated volumes. The kidneys and spinal cord showed no radiation effects. The authors conclude that neutron irradiation can provide a good local response with marked regression and fibrosis of the tumor. This response, coupled with many deaths due to metastases, suggests that combined treatment with neutrons and chemotherapy would be worth exploring.


International Journal of Radiation Oncology Biology Physics | 1984

Response of sarcomas of bone and of soft tissue to neutron beam therapy

Lionel Cohen; Frank R. Hendrickson; Joanne Mansell; Parvathy D. Kurup; Miguel Awschalom; I. Rosenberg; Randall K. Ten Haken

A total of 51 patients were treated at Fermilab for sarcoma of bone (25 patients) and soft tissue (26 patients). Neutrons were delivered in twice weekly fractions over 6-7 weeks to total doses between 18 and 26 Gy. Long-term local control (greater than 2 years) was achieved in 24 patients (47%). Overall local control rates were 44% in the bone sarcomas and 50% in the soft tissue tumors. Chondrosarcoma appeared relatively more responsive with 9 out of 16 (56%) controlled, compared to osteogenic sarcoma with 2 out of 9 (22%) controlled. Among the soft tissue tumors, liposarcoma (5/7 controlled) and neurogenic sarcoma (3/3 controlled) appear to be more responsive than other tumors. The overall survival rate was 40% in the entire series. These results are comparable with international experience in neutron therapy of sarcomas of bone and soft tissues. Out of 263 soft tissue sarcomas treated with neutrons only to full dosage throughout the world, 152 (58%) were locally controlled. Similarly out of 74 sarcomas of bone so treated, 44 (60%) were controlled.


International Journal of Radiation Oncology Biology Physics | 1989

Failure of accelerated neutron therapy to control high grade astrocytomas

K.R. Saroja; Joanne Mansell; Frank R. Hendrickson; Lionel Cohen; A. J. Lennox

Sixty-two patients with high grade malignant astrocytoma were treated with fast neutrons using three different treatment schemes to evaluate the effect of shortening the overall time. Dose and fraction number were kept constant. The total dose was 16-18 neutron Gy delivered in six fractions, weekly for 6 weeks, twice a week over 3-4 weeks, or three times a week over 2 weeks. There were no obvious differences in survival times among the three groups. We conclude that accelerated neutron therapy does not improve survival of patients with grade 3 and 4 astrocytoma.


International Journal of Radiation Oncology Biology Physics | 1981

Fast neutrons in the treatment of salivary gland tumors

Raman Kaul; Frank R. Hendrickson; Lionel Cohen; I. Rosenberg; Randall K. Ten Haken; Miguel Awschalom; Joanne Mansell

Fast neutrons were used in the management of 30 patients with advanced salivary gland tumors. Twenty-two patients are the subject of this analysis. Neutrons were used as the primary mode of management in only seven patients. The remaining patients either had recurrent disease after surgery and/or radiation, or received post-operative treatment with neutrons. After a minimum follow-up of one year, 66% of the patients are alive with no evidence of disease. Control in the treatment volume is as high as 72%, which suggests a significant improvement in the local control of advanced salivary gland tumors. However, longer periods of observation are necessary for more definitive conclusions.


International Journal of Radiation Oncology Biology Physics | 1985

Tolerance of the human spinal cord to high energy p(66)Be(49) neutrons

Lionel Cohen; Randall K. Ten Haken; Joanne Mansell; Sulochana D. Yalavarthi; Frank R. Hendrickson; Miguel Awschalom

The risk of post irradiation myelopathy was evaluated in 76 patients followed for 1-5 years after neutron irradiation of the cervical and thoracic regions. No overt myelopathy was observed. Forty-six patients received doses (central cord dose) in excess of 10 Gy, 9 received doses in excess of 12 Gy, and 5 received doses between 13 and 17 Gy, all without any evidence of spinal cord injury. On careful questioning, a subjective transient neuropathy (a tingling sensation in one extremity) was reported by 6 patients, but this was apparently unrelated to dose. A review of available literature revealed a total of 14 patients with myelopathy, 13 of whom received doses in excess of 13 Gy delivered with relatively low energy neutrons generated by the deuteron + beryllium reaction. It is concluded from these studies that the tolerance limit for the human spinal cord irradiated with high energy [p(66)Be(49)] neutrons is close to 15 Gy, above which the risk of cord injury becomes significant. Central cord doses of 13 Gy or less appear to be well tolerated with little, if any, risk of myelopathy. These conclusions are valid for a treatment time of 4 weeks or more with two or more fractions per week (9 or more fractions). The RBE for the human spinal cord irradiated under the above conditions compared with conventionally fractionated photon therapy does not exceed 4.0.


International Journal of Radiation Oncology Biology Physics | 1988

Re-irradiation of locally recurrent tumors with fast neutrons☆

K.R. Saroja; Frank R. Hendrickson; Lionel Cohen; Joanne Mansell; A. J. Lennox

Forty-six patients with locally recurrent disease were re-irradiated with fast neutrons at Fermilab. All had received prior radical radiation therapy either with or without surgery. Six were palliative. Forty patients treated with curative intent were analyzed for local response, survival, and complications. The overall response rate was 78% (31/40); 50% (20/40) had a complete local response. Ten of 16 patients (63%) with non-epidermoid carcinomas in the head and neck regions had complete response, whereas only nine of twenty patients (45%) with epidermoid carcinomas were complete responders. In a subset of 12 patients with salivary gland type tumors, 10 had a complete response (83%). Two of these 10 patients are alive beyond 5 years. Observed median survival for the forty patients was 9.3 months, and for complete responders 14.4 months. Observed median survival for partial responders was only 7.5 months. Four of six patients treated for palliation had significant subjective improvement. Significant morbidity, Grade III or greater (EORTC/RTOG scale), was seen in only 10 patients (25%), and this was found to depend directly on the total dose delivered. We conclude that neutron beam therapy can be used as a therapeutic modality for patients with recurrent tumors with an acceptable degree of morbidity.


International Journal of Radiation Oncology Biology Physics | 1984

Response of epidermoid and non-epidermoid cancers of the head and neck to fast neutron irradiation: The Fermilab experience

Parvathy D. Kurup; Joanne Mansell; Randall K. Tenhaken; Frank R. Hendrickson; Lionel Cohen; Miguel Awschalom; I. Rosenberg

One hundred and six patients with locally advanced cancers of the head and neck were treated with neutrons at the Fermilab Neutron Therapy Facility. Of these, 44 patients were previously untreated, 33 were recurrent following attempted surgery and 29 patients had previously received a full course of radiation therapy with conventional radiation. Results were analyzed to study the influence of stage, previous management, site of origin and tumor histology on local control of the disease. The most significant factor determining the outcome in this series of patients is the histological type. For epidermoid carcinoma, long term local control was achieved in 17/35 patients (49%) in the previously unirradiated group. With non-epidermoid tumors (adenocarcinoma, cylindroma, muco-epidermoid carcinoma), the local control rate was 28/39 (72%). Disease-free survival analysis also shows a survival advantage in non-epidermoid lesions treated with neutrons. It is concluded that neutron beam therapy may probably be the treatment of choice for non-resectable or recurrent non-epidermoid cancers of the head and neck and requires a clinical trial to establish this observation.


International Journal of Radiation Oncology Biology Physics | 1990

Normal tissue reactions and complications following high-energy neutron beam therapy II: Complication rates adjusted for censoring

Timothy E. Schultheiss; Lionel Cohen; Joanne Mansell

A dose response analysis was performed on patients at risk for significant radiation injuries following neutron radiotherapy. Complication rates were calculated at various dose intervals using a maximum likelihood method that is formally equivalent to the product limit estimator of survival. The variance of each complication rate was used to weight a logistic regression on log dose. The treatment sites that were analyzed were head and neck, pelvis, thorax, and pancreas. Except for osteomyelitis of the mandible, complications of all types were considered collectively at each site and dose increment since there were too few complications to determine dose response functions for individual types of injuries. The head and neck was observed to be the site with the highest tolerance to radiation whereas the thorax was the most sensitive site.


International Journal of Radiation Oncology Biology Physics | 1981

Late reactions and complications in patients treated with high energy neutrons p (66MeV)Be(49MeV)

Lionel Cohen; Frank R. Hendrickson; Joanne Mansell; Miguel Awschalom; Allen Hrejsa; Raman Kaul; I. Rosenberg

Abstract Eight of 22 patients who were followed for a year or more after neutron doses in excess of 20 Gy slowed significant late reactions. Late reactions were also observed in 6 of 20 patients who were treated with a neutron boost of 7.5 Gy following 50 Gy of photons for intraoral cancer, and in 5 of 9 ‘mixed beam’ patients who received 9 to 11 neutron Gy with 45 to 50 photon Gy concurrently over a seven week treatment period. Nine of 20 patients who were treated with curative doses of neutrons following recurrence after radical photon therapy had excessively severe late effects. In the neutron only group, a tentative isoeffect line (dose versus fractions) for cutaneous fibrosis could be drawn with an origin at 20 Gy and a slope of 0.04. A time-dose factors analysis of the whole series suggested that a TDF of 120 (±10) defined the threshold for severe stromal fibrosis and associated complications.

Collaboration


Dive into the Joanne Mansell's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

James S. Nelson

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge